KLRB1 and prostate adenocarcinoma: On the contrary, patients with low levels of CD161 expression associated with shorter OS in ACC, Breast invasive carcinoma (BRCA), BLCA, CESC, Cholangiocarcinoma (CHOL), KIRC, HNSC, KIRP, LUAD, LIHC, Mesothelioma (MESO), PAAD, OV, READ, Pheochromocytoma and Paraganglioma (PCPG), PRAD, Sarcoma (SARC), Uterine Corpus Endometrial Carcinoma (UCEC), SKCM, Thyroid carcinoma (THCA, Figures 2A, B, S1).